ERBB3 and non-small cell lung carcinoma: In the HERTHENA-Lung01 phase 2 study, a total of 225 patients with EGFR-mutated NSCLC previously treated with TKIs received HER3-DXd at a dose of 5.6 mg/kg once every 3 weeks [23].